Pages that link to "Q42985571"

The following pages link to Influence of chronic coinfection with hepatitis B and C virus on liver histology. (Q42985571):

Displaying 39 items.

• The nature and consequences of coinfection in humans (Q24609582) (← links)
• KASL clinical practice guidelines: management of hepatitis C (Q26752471) (← links)
• KASL clinical practice guidelines: management of chronic hepatitis B (Q26752475) (← links)
• What's new in hepatitis C virus infections in children? (Q26782000) (← links)
• Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals (Q26782033) (← links)
• Role of occult hepatitis B virus infection in chronic hepatitis C (Q26823538) (← links)
• Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions (Q29036593) (← links)
• Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression (Q34263370) (← links)
• Hepatitis B virus and hepatitis C virus dual infection (Q34404975) (← links)
• Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus (Q34420891) (← links)
• The influence of hepatitis B and C virus coinfection on liver histopathology in children (Q35100262) (← links)
• Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population (Q35793834) (← links)
• Impact of comorbidities on the severity of chronic hepatitis B at presentation (Q35886670) (← links)
• KASL Clinical Practice Guidelines: Management of chronic hepatitis B. (Q36153966) (← links)
• Optimizing management strategies in special patient populations (Q36382644) (← links)
• HBV plus HCV, HCV plus HIV, HBV plus HIV. (Q36410579) (← links)
• The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. (Q36575228) (← links)
• Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment (Q37132382) (← links)
• MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin (Q37281927) (← links)
• Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study (Q37356018) (← links)
• Liver biopsy findings in chronic hepatitis B. (Q37462537) (← links)
• Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. (Q38235178) (← links)
• Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals (Q38779980) (← links)
• Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals (Q38805093) (← links)
• Interference of replication between hepatitis B and C viruses in patients infected with HIV (Q39543611) (← links)
• Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury (Q40556586) (← links)
• Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection (Q42245958) (← links)
• A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. (Q42981671) (← links)
• High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe (Q44170366) (← links)
• Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. (Q44358596) (← links)
• Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up (Q44712043) (← links)
• Longer survival of liver transplant recipients with hepatitis virus coinfections (Q45405259) (← links)
• Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study (Q46959082) (← links)
• KASL clinical practice guidelines: management of hepatitis C. (Q51836024) (← links)
• INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. (Q54216584) (← links)
• 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C (Q58788714) (← links)
• A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort (Q60955480) (← links)
• Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy (Q89899473) (← links)
• Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV) (Q90193786) (← links)